XXXX decreases bone blood flow.

@entity1501 @entity1255 @entity170 @entity2186 @entity5784 @entity35 @entity3562 @entity551
Elevated plasma levels of @entity1255 ( @entity5784 ), known as @entity3562 ( @entity3562 ), are associated with @entity170 . A decrease in bone blood flow is a potential cause of compromised bone mechanical properties. Therefore, we hypothesized that @entity3562 decreases bone blood flow and biomechanical properties. To test this hypothesis, male @entity35 were treated with @entity5784 (0.67 g/L) in drinking water for 8 weeks. Age-matched @entity35 served as controls. At the end of the treatment period, the @entity35 were anesthetized. Blood samples were collected from experimental or control @entity35 . Biochemical turnover markers (body weight, @entity5784 , @entity2186 , and @entity1501 ) were measured. Systolic blood pressure was measured from the right carotid artery. Tibia blood flow was measured by laser Doppler flow probe. The results indicated that @entity5784 levels were significantly higher in the @entity5784 -treated group than in control @entity35 , whereas @entity2186 levels were lower in the @entity5784 -treated group compared with control @entity35 . There was no significant difference in @entity1501 concentration and blood pressure in @entity5784 -treated versus control @entity35 . The tibial blood flow index of the control group was significantly higher (0.78    0.09 flow unit) compared with the @entity5784 -treated group (0.51    0.09). The tibial mass was 1.1    0.1 g in the control group and 0.9    0.1 in the @entity5784 -treated group. The tibia bone density was unchanged in @entity5784 -treated @entity35 . These results suggest that @entity5784 causes a @entity551 , which contributes to compromised bone biomechanical properties.
